Eventide Gilead N
Name
Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
Vitals
YTD Return
11.2%
1 yr return
-3.5%
3 Yr Avg Return
0.5%
5 Yr Avg Return
3.6%
Net Assets
$3.73 B
Holdings in Top 10
30.5%
52 WEEK LOW AND HIGH
Expenses
OPERATING FEES
Expense Ratio 1.31%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover 19.00%
Redemption Fee N/A
Min Investment
Standard (Taxable)
$1,000
IRA
$1,000
Fund Classification
Fund Type
Open End Mutual Fund
Name
Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
ETGLX - Profile
Distributions
- YTD Total Return 11.2%
- 3 Yr Annualized Total Return 0.5%
- 5 Yr Annualized Total Return 3.6%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio -0.85%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annually
Fund Details
-
Legal NameEventide Gilead Fund
-
Fund Family NameEventide Funds
-
Inception DateJul 08, 2008
-
Shares OutstandingN/A
-
Share ClassN
-
CurrencyUSD
-
Domiciled CountryUnited States
-
ManagerFinny Kuruvilla
ETGLX - Performance
Return Ranking - Trailing
| Period | ETGLX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 11.2% | -49.0% | 26.9% | 51.01% |
| 1 Yr | -3.5% | -80.5% | 2166.7% | 76.62% |
| 3 Yr | 0.5%* | -41.2% | 180.5% | 23.33% |
| 5 Yr | 3.6%* | -29.6% | 82.6% | 24.37% |
| 10 Yr | 9.8%* | -18.1% | 15.5% | 6.84% |
* Annualized
Return Ranking - Calendar
| Period | ETGLX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2022 | -37.4% | -85.6% | 21888.9% | 84.14% |
| 2021 | 2.2% | -52.0% | 800.0% | 33.39% |
| 2020 | 15.4% | -100.0% | 195.3% | 11.85% |
| 2019 | 6.7% | -100.0% | 9.5% | 27.81% |
| 2018 | -1.6% | -33.3% | 36.8% | 20.16% |
Total Return Ranking - Trailing
| Period | ETGLX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 11.2% | -54.7% | 26.9% | 51.01% |
| 1 Yr | -3.5% | -80.5% | 2166.7% | 76.74% |
| 3 Yr | 0.5%* | -41.2% | 180.5% | 23.76% |
| 5 Yr | 3.6%* | -28.4% | 82.6% | 26.80% |
| 10 Yr | 10.0%* | -16.9% | 15.6% | 10.26% |
* Annualized
Total Return Ranking - Calendar
| Period | ETGLX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2022 | -37.4% | -85.6% | 21888.9% | 84.14% |
| 2021 | 2.2% | -52.0% | 800.0% | 33.39% |
| 2020 | 15.4% | -100.0% | 195.3% | 11.85% |
| 2019 | 6.7% | -100.0% | 9.5% | 27.81% |
| 2018 | -1.6% | -33.3% | 36.8% | 40.32% |
NAV & Total Return History
ETGLX - Holdings
Concentration Analysis
| ETGLX | Category Low | Category High | ETGLX % Rank | |
|---|---|---|---|---|
| Net Assets | 3.73 B | 710 K | 85.5 B | 22.73% |
| Number of Holdings | 77 | 20 | 3702 | 49.75% |
| Net Assets in Top 10 | 1.37 B | 259 K | 10.9 B | 19.26% |
| Weighting of Top 10 | 30.54% | 5.5% | 92.1% | 29.65% |
Top 10 Holdings
- Us Bank Mmda - Usbgfs5 5.98%
- Us Bank Mmda - Usbgfs5 5.98%
- Us Bank Mmda - Usbgfs5 5.98%
- Us Bank Mmda - Usbgfs5 5.98%
- Us Bank Mmda - Usbgfs5 5.98%
- Us Bank Mmda - Usbgfs5 5.98%
- Us Bank Mmda - Usbgfs5 5.98%
- Us Bank Mmda - Usbgfs5 5.98%
- Us Bank Mmda - Usbgfs5 5.98%
- Us Bank Mmda - Usbgfs5 5.98%
Asset Allocation
| Weighting | Return Low | Return High | ETGLX % Rank | |
|---|---|---|---|---|
| Stocks | 92.95% | 23.99% | 100.52% | 93.80% |
| Cash | 4.87% | -0.52% | 26.94% | 11.22% |
| Bonds | 1.41% | 0.00% | 44.75% | 0.84% |
| Other | 0.55% | -2.66% | 23.05% | 8.88% |
| Preferred Stocks | 0.21% | 0.00% | 2.30% | 6.53% |
| Convertible Bonds | 0.00% | 0.00% | 0.40% | 33.67% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | ETGLX % Rank | |
|---|---|---|---|---|
| Technology | 43.15% | 0.04% | 62.17% | 5.53% |
| Industrials | 20.29% | 0.00% | 38.23% | 10.05% |
| Healthcare | 17.38% | 0.00% | 43.77% | 54.27% |
| Consumer Cyclical | 8.82% | 0.00% | 57.41% | 86.77% |
| Utilities | 5.62% | 0.00% | 12.94% | 1.17% |
| Real Estate | 2.35% | 0.00% | 19.28% | 50.42% |
| Consumer Defense | 1.94% | 0.00% | 16.40% | 55.61% |
| Energy | 0.44% | 0.00% | 62.10% | 57.45% |
| Financial Services | 0.00% | 0.00% | 43.01% | 96.82% |
| Communication Services | 0.00% | 0.00% | 18.33% | 90.28% |
| Basic Materials | 0.00% | 0.00% | 17.25% | 82.41% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | ETGLX % Rank | |
|---|---|---|---|---|
| US | 81.67% | 23.38% | 100.52% | 94.47% |
| Non US | 11.28% | 0.00% | 35.22% | 8.71% |
Bond Sector Breakdown
| Weighting | Return Low | Return High | ETGLX % Rank | |
|---|---|---|---|---|
| Cash & Equivalents | 75.64% | 0.00% | 100.00% | 95.04% |
| Corporate | 24.36% | 0.00% | 100.00% | 4.41% |
| Derivative | 0.00% | 0.00% | 4.48% | 33.64% |
| Securitized | 0.00% | 0.00% | 30.57% | 32.35% |
| Municipal | 0.00% | 0.00% | 0.02% | 32.35% |
| Government | 0.00% | 0.00% | 99.86% | 32.54% |
Bond Geographic Breakdown
| Weighting | Return Low | Return High | ETGLX % Rank | |
|---|---|---|---|---|
| US | 1.41% | 0.00% | 36.45% | 0.84% |
| Non US | 0.00% | 0.00% | 8.30% | 33.50% |
ETGLX - Expenses
Operational Fees
| ETGLX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 1.31% | 0.02% | 2.69% | 23.39% |
| Management Fee | 0.95% | 0.00% | 1.50% | 90.05% |
| 12b-1 Fee | 0.20% | 0.00% | 1.00% | 28.96% |
| Administrative Fee | N/A | 0.00% | 0.40% | 48.52% |
Sales Fees
| ETGLX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 0.00% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 5.00% | N/A |
Trading Fees
| ETGLX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 2.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| ETGLX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 19.00% | 0.00% | 417.06% | 17.62% |
ETGLX - Distributions
Dividend Yield Analysis
| ETGLX | Category Low | Category High | ETGLX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.00% | 0.00% | 2.54% | 40.20% |
Dividend Distribution Analysis
| ETGLX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annually | Annually | Monthly | Annually |
Net Income Ratio Analysis
| ETGLX | Category Low | Category High | ETGLX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -0.85% | -2.24% | 2.75% | 71.40% |
Capital Gain Distribution Analysis
| ETGLX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
ETGLX - Fund Manager Analysis
Managers
Finny Kuruvilla
Start Date
Tenure
Tenure Rank
Jul 08, 2008
13.9
13.9%
Finny Kuruvilla, M.D., Ph.D., has been primarily responsible for the day-to-day management of the Gilead Fund and Healthcare & Life Sciences Fund since inception. Dr. Kuruvilla has been the Managing Partner of the Adviser since its inception in 2008. Dr. Kuruvilla possesses a diverse background in quantitative methods, with applications focused on innovations in science, engineering, and medicine. He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master’s degree in Electrical Engineering and Computer Science from MIT, and a bachelor’s degree from Caltech in Chemistry. From 2005-2008, Dr. Kuruvilla was a clinical fellow at the Brigham and Women's Hospital and a postdoctoral scientist at MIT. As an avid proponent of values-based investing, Dr. Kuruvilla has established rigorous standards in seeking out the most ethical companies at the outset of the stock selection process. In addition to his role with the Adviser, Dr. Kuruvilla is a founder, financial sponsor, and Board Director of Sattler College, a four-year college in Boston, Massachusetts, opened in 2018. Dr. Kuruvilla also contributes to the college in a limited faculty role. From 2008-2016, Dr. Kuruvilla provided research services as an employee of Clarus Ventures, a healthcare and life sciences venture capital firm. From 2006-2008, Dr. Kuruvilla was a research fellow at the Broad Institute of Harvard and MIT.
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.04 | 36.3 | 9.17 | 2.25 |